Primmune Therapeutics
PrivateLast Round
Series B
Jan 26, 2026
Total Funding Raised
$93.1M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Primmune Therapeutics is a biotechnology company that develops orally administered toll-like receptor 7 (TLR7) agonists to enhance innate immunity for the treatment of cancer and viral diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Defense Tech
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Primmune Therapeutics Comparables
Compare Primmune Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MonTa Biosciences | 80% | |
| Inimmune | 80% | |
| Apros Therapeutics | 78% |
Primmune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 26, 2026 | ||||
| Grant | Mar 20, 2024 | ||||
| Series A | Jan 12, 2021 | ||||
| Series A | Oct 27, 2020 | ||||
| Seed | Mar 2, 2020 |
Key People
Founding team and executive leadership
Primmune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CAM Capital | Series A, Seed |
| BioRock Ventures | Series A, Seed |
| Bioqube Ventures | Series B, Series A |
| Oberland Capital Management | Series B, Series A |
| BioBrit | Series A, Seed |
| Polaris Partners | Series A |
| Samsara BioCapital | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 157% MoM.
- Feb 5, 2026
Chris Krueger appointed as Executive Chairman of the Board.
Primmune Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Primmune Therapeutics's valuation, stock price, and market status.
Is Primmune Therapeutics a public or private company?
Primmune Therapeutics is a private company.
What is the current stock price of Primmune Therapeutics?
Primmune Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Primmune Therapeutics worth (valuation)?
Valuation information for Primmune Therapeutics is not publicly available.
Can I buy Primmune Therapeutics stock?
Primmune Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Primmune Therapeutics's last funding round?
Primmune Therapeutics's most recent funding round was Series B Extension on January 26, 2026.
Who are the main investors in Primmune Therapeutics?
Key investors in Primmune Therapeutics include CAM Capital, BioBrit, Polaris Partners.
Will Primmune Therapeutics IPO soon?
No public IPO plans have been announced for Primmune Therapeutics.
How can I track Primmune Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Primmune Therapeutics's secondary market activity and sign up for updates.